Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18429473 | 1.00 | KMT2A (0.68) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL17177621 | 0.93 | KMT2A (0.76) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL29485093 | 0.92 | KMT2A (0.74) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL13525077 | 0.91 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL3140809 | 0.91 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL178687 | 0.91 | KMT2A (0.81) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL29397906 | 0.91 | KMT2A (0.81) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL29423575 | 0.91 | KMT2A (0.81) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL8654488 | 0.91 | KMT2A (0.84) | KMT2AEPHX2CASP3OPRD1 | |
| SCHEMBL29975343 | 0.89 | KMT2A (0.60) | KMT2AEPHX2CASP3OPRD1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12379357-B2 | Method for quantifying amino group-containing compound protected by protecting group having Fmoc skeleton | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-05 | — | — | US | disclosed |
| CN-114585916-B | Method for quantifying compound containing amino group protected with protecting group having Fmoc skeleton | 中外制药株式会社 | 2025-03-11 | — | — | CN | disclosed |
| US-20240151696-A1 | METHOD FOR QUANTIFYING AMINO GROUP-CONTAINING COMPOUND PROTECTED BY PROTECTING GROUP HAVING FMOC SKELETON | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4144747-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698032-A | Efficient peptide condensation of difficult sequences | 中外制药株式会社 | 2023-02-03 | — | — | CN | disclosed |
| EP-4046982-A1 | METHOD FOR QUANTIFYING AMINO GROUP-CONTAINING COMPOUND PROTECTED BY PROTECTING GROUP HAVING FMOC SKELETON | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-24 | — | — | EP | disclosed |
| CN-114585916-A | Method for quantifying compound having amino group protected with protecting group having Fmoc skeleton | 中外制药株式会社 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | KMT2A 3727/4885EPHX2 3850/4885CASP3 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.